Trastuzumab deruxtecan boosts HER2-positive metastatic breast cancer PFS

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 18 / Springer Healthcare

Trastuzumab deruxtecan boosts HER2-positive metastatic breast cancer PFS

Oncology Breast Cancer ESMO-2021

Description

Matteo Lambertini comments on the DESTINY-Breast03 study finding that trastuzumab deruxtecan significantly extends HER2-positive metastatic breast cancer progression-free survival compared with trastuzumab emtansine

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.